OHRP interim Phase 2 wet-AMD data due Tuesday + updates for ASPX XNPT GNCA

Jun 24, 2014 No Comments

Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) announced that it will host a conference call and webcast on Tuesday, June 24th at 8:30am EST to discuss Squalamine interim Phase 2 data in wet age-related macular degeneration (wet-AMD). Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX) maintained previous guidance that they expect data from their Phase 3 ARC-HD trial of SD-809 for the […]

Read more

CBST FDA Approval. OPK conference call Tue regarding hGH-CTP. TTPH IGNITE 2 trial update + MACK.

Jun 21, 2014 No Comments

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced the FDA approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). Cubist Pharmaceuticals also announced that the FDA has accepted their New Drug Application (NDA) of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections, under Priority […]

Read more

INSM granted Breakthrough Therapy Designation. NRX initiates Phase 3 trial + PLX news

Jun 19, 2014 No Comments

NephroGenex, Inc. (Nasdaq:NRX) announced it has initiated patient enrollment in the first of two pivotal Phase 3 studies in the PIONEER program for oral Pyridorin. The trial will evaluate the safety and efficacy of Pyridorin in slowing disease progression in patients with diabetic nephropathy. Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) announced that the first Gaucher patient has been […]

Read more

ETRM Advisory Committee results. EXAS approval decision due August. ECYT vintafolide rights returned by MRK + RCPT GALE news

Jun 18, 2014 No Comments

EnteroMedics Inc. (NASDAQ: ETRM) announced that the FDA Advisory Gastroenterology and Urology Devices Panel (GUDP) voted 8 to 1 in favour that the device is safe, 4 to 5 against its efficacy and 6 to 2 in favour, with 1 abstention, that the relative benefits outweighed the relative risk. The FDA is not bound by the GUDP’s recommendation, but will take it into consideration when […]

Read more

FLML assigned August PDUFA date. RVNC offering. Trial updates for ATLN CLVS

Jun 17, 2014 No Comments

Flamel Technologies (NASDAQ: FLML) announced today that the FDA has assigned a PDUFA date of August 6, 2014 for its second New Drug Application (NDA). The company had received a Complete Response Letter (CRL) to its NDA on its April 28, 2014. Flamel resubmitted the NDA on June 6, 2014 and FDA classified the CRL resubmission as a Class […]

Read more

NAVB FDA Approval. ENTA granted priority review PDUFA. KOOL offering. ENMD ticker change.

Jun 14, 2014 No Comments

Navidea Biopharmaceuticals, Inc.(NYSE MKT: NAVB) announced that the FDA has approved the Supplemental New Drug Application (sNDA) for the expanded use of Lymphoseek Injection indicated for guiding sentinel lymph node (SLN) biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) announced that the New Drug Application (NDA) for […]

Read more

Advisory Committee votes to not require CVOTs. HPTX Phase 3 data due 1Q 2015.

Jun 13, 2014 No Comments

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Progenics Pharmaceuticals (NASDAQ:PGNX) and Nektar Therapeutics (NASDAQ:NKTR) reported voting results from the Anesthetic and Analgesic Drug Products Advisory Committee of the FDA. They announced that a majority of  Advisory Committee members voted to not require cardiovascular outcomes trials (CVOTs) for PAMORAS being developed for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain. The […]

Read more

OREX PDUFA date delayed by three months. FDA lifts GERN clinical hold.

Jun 12, 2014 No Comments

Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that the FDA has extended its review of the resubmitted New Drug Application (NDA) for NB32, for weight loss. The new PDUFA date is September 11, 2014. The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes […]

Read more

NPSP Adcom meeting date change. ACHN sovaprevir clinical hold lifted + ALKS news

Jun 11, 2014 No Comments

NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) announced that the FDA has shifted the tentative date for the Natpara Advisory Committee Meeting from July 24 to September 12, 2014. The PDUFA date remains unchanged at October 24, 2014. Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced that the FDA has removed the clinical hold on their Phase 2 trial of sovaprevir, in […]

Read more